Compare Fastly Inc (FSLY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Natera Inc. Common Stock — how do they compare? Fastly Inc trades at $24.34 (market cap $3.98B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 14.3× Fastly Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Fastly Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Natera Inc. Common Stock for 0 Days on average.
| FSLY | NTRA | |
|---|---|---|
Market Cap | $3.98B | $57.03B |
Volume | 6,072,668 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $33.50 | $425.64 |
52-Week Low | $7.86 | $179.42 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $4.04B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $27.09, up 2.5% with bullish technical signals and strong earnings beats. The stock shows improving fundamentals with revenue growth from $544M to $624M (2024-2025) and narrowing losses. Recent investor day highlighted AI-driven growth targets of $1.1-1.3B revenue by 2029. Technical indicators show bullish moving averages with support at $25 and resistance at $28.
Outlook remains positive with analyst consensus at $28.33 target, though risks include persistent net losses and insider selling. The company's edge cloud platform benefits from AI traffic growth, but profitability challenges and competitive pressures require monitoring. Institutional sentiment is mixed with 33% buy ratings amid ongoing transformation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
